AwardTape · Defense awards · Novartis · Advanced Accelerator Applications USA Inc
Advanced Accelerator Applications USA Inc: $4.2M in DoD and DHS awards (this registration)
This registration, Advanced Accelerator Applications USA Inc, holds 8 DoD and DHS prime awards with $4.2M obligated Nov 14, 2023 to May 13, 2025. Largest category: Drugs and biologicals at $3.0M; largest buyer: Department of the Army at $2.6M.
| Obligated FY2024+ | $4.2M |
|---|---|
| Awards | 8 |
| FY2024 | $3.5M |
| FY2025 | $711K |
| FY2026 to date | $0 |
| Lifetime obligated on these awards | $4.2M |
| Parent company | Novartis: $12.3M in DoD and DHS awards since FY2024 across 2 registrations |
| First and latest action | Nov 14, 2023 · May 13, 2025 |
| # | Category | Obligated FY2024+ | Awards | Share |
|---|---|---|---|---|
| 1 | Drugs and biologicals | $3.0M | 5 awards | 72% |
| 2 | Diagnostics and lab supplies | $1.2M | 3 awards | 28% |
| # | Agency | Obligated FY2024+ | Awards | Share |
|---|---|---|---|---|
| 1 | Department of the Army | $2.6M | 1 awards | 61% |
| 2 | Defense Health Agency | $1.7M | 7 awards | 39% |
| Award | Obligated FY2024+ | What | Agency | Category | Latest action |
|---|---|---|---|---|---|
| W81K0023C0013 definitive contract | $2.6M | Pluvicto (lutetium lu-177 vipivotide tetraxetan) and lutathera (lutetium lu-177 dotatate) | Army | Drugs and biologicals | Jul 25, 2024 DoD 90d |
| HT001425P0018 purchase order | $498K | Six branded nuclear medicine fda approved lutathera and pluvicto. | Defense Health Agency | Diagnostics and lab supplies | Dec 4, 2024 DoD 90d |
| HT001424P0129 purchase order | $482K | Pluvicto lutetium lu177 vipivotide tetra | Defense Health Agency | Diagnostics and lab supplies | Apr 26, 2024 DoD 90d |
| HT941024P0018 purchase order | $236K | Lutathera lutetium lu 177 dotatate | Defense Health Agency | Drugs and biologicals | Nov 15, 2023 DoD 90d |
| HT941024P0210 purchase order | $227K | Lutetium lu 177 vipivotide tetraxetan | Defense Health Agency | Drugs and biologicals | Aug 16, 2024 DoD 90d |
| HT001425P0095 purchase order | $212K | Lutathera lutetium a radioactive drug used to treat somatostatin for walter reed. | Defense Health Agency | Diagnostics and lab supplies | May 13, 2025 DoD 90d |
| HT941024A0014 blanket purchase agreement | $0 | Pluvicto and lutathera injection | Defense Health Agency | Drugs and biologicals | Dec 15, 2024 DoD 90d |
| N0025922F0027 BPA call | -$3.5K | Netspot (ga-68 dotatate) unit dose(4 each) | Defense Health Agency | Drugs and biologicals | Apr 23, 2024 DoD 90d |
Source: USAspending.gov prime award data (FPDS), DoD and DHS contracts, orders and IDVs with any action since Oct 1, 2023. Obligated FY2024+ sums the obligations on those actions; total obligated is the award's lifetime figure. DoD contract actions publish on USAspending about 90 days after signing (DFARS PGI 204.6), so the latest DoD actions here trail the calendar by about 3 months. Data as of Oct 9, 2026.
Terminal: filters, alerts and CSV export for this company's awards.
7 days free for first-time subscribers, then $49/mo. Card required. Cancel before day 8 and you pay nothing.
Start free trial